Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Then $10 after approval, then $20 for BO?
Good start. Let's see how next week goes. Would love to be up and over $1 before approval.
It's honestly hilarious
, Nice try but you better do better than that .
Covering your ass for that ridiculous statement ?? Naw not you, mister truthful lol
attilathehunt WOW you have really gone out on a limb with that outrageous statement. If proves to be a non-event come Monday you will be added to my ignore list as you would have exceeded the limits of common decency on a message board. imo
Or confirm the great significance to NWBO of a NON-clinical lab audit spreadsheet that was posted a couple of years ago and who kept insisting it was significant. Since then that poster has been on ignore no matter what possible gems that possibly can be unearthed.
Is this the only way you want to show how clever you are?
If you were smart, you would take advantage of the current low sp and increase your puny position. But this would never happen since you are on the other side of the fence.
apparently LC, you have serious doubts based on the lack of side effects
that the science is strong for this company.
So please tell us whether you have been suffering side effects
every time that your immune system which is your personal therapy has
eliminated the viruses and bacteria that were responsible for the various
infectious diseases that have attacked you throughout your life.
Apparently, evolution saw to it that your immune defense mechanisms
are not accompanied by substantial side effects.
Why then would we expect the stimulated DCs directed against human
tumor antigens to act any differently and elicit an immune response that
cause side effects?
I think that the company will negotiate the price regardless of the production process. It may not be quite as profitable if made manually, but have no doubt, it will be quite profitable.
Why? Because developmental cost is strongly considered when establishing the price. The BP'S have done an amazing job at keeping the prices up after recouping their initial investment many times over. Many products sell for far more than when they were initially approved, and the politicians don't seem to care as long as their campaign contributions keep coming in.
Gary
The only excuse would be if you were a Brit, down at the Old Nags Head, enjoying a Friday night tipple, trying to figure out American politics and someone read this post. Who the F is Lowes, but what the hell I’m all in. Blimey.
Preparations for Regulatory Inspections. As previously reported, preparations for regulatory inspections associated with the MAA have been a major focus of the Company's activities this year to date, including mock inspections.
Inspections by MHRA are scheduled to take place in both the
U.S. and the U.K.
Lol…. That was best post of the week .
you probably work with ex, just ask him, if you want my opinion.
FeMike That theory is absurd. You are saying they are going to buy from the local Lowes for construction on a on a huge scale and hundreds of freezers.…stop the friggin BS
My wife said it was probably Nancy Pelosi.
LOL!
I sure hope you are right this time . It has been an extremely long wait
flipper44,
No worries. Not inside info. Best wishes.
learningcurve2020,
Desperate retail investors? Hardly! Excited retail investors and NWBO management excited about sharing good news turned into bad by a hack attack and short manipulation of the share price. This subject being part of the basis for the ongoing court case against 7 market makers. Go fish; ). Best wishes.
Don’t share it if you are going to talk about inside info. I assume you are speaking in more general terms about looking for other examples.
Just a complete shit-clown post with no perspective beyond the superficial.
flipper44,
Nothing comes to mind but then again NWBO is in a rather unique position. Someone else I talked to did mention something along this line though with a development agreement he was aware of. I’ll check with him this weekend and get the details. Best wishes.
learningcurve2020,
Rapid expansion and value added. 2024 is just the first stage; ). Best wishes.
Sarc.
(I’ll never buy LG again for a couple years. Just had a Kenmore go out and it had the problematic LG linear compressor in it.)
Only 7 dang years.
Yeah!!!!...The game continues.
>>I think 2025-2026 are going to be very interesting years
Zadie420,
I’m telling you that the very first Direct trial, likely a basket, will be more than enough to convince that no one has enough cash to buy NWBO. That is the real threat here. How much time before these truths become self evident if tumors are completely dead or gone 3 months into treatment?; ). I think 2025 into 2026 will be very interesting for NWBO. Best wishes.
PS- I am only trying to find some COMMON ground between us all.
I Like iT! Plausible
Why would he think that with virtually no professional coverage and nothing but desperate retail investors?
>>Reasonable to say that Les expected a significant increase in value after news and tried to time the distribution to that
learningcurve2020,
Are you familiar with required GRAT distributions especially with regard to this situation? If not, then all you have is questions with no answers. What I can say is that GRAT distributions work best for tax advantage when there has been a significant increase in value. Reasonable to say that Les expected a significant increase in value after news and tried to time the distribution to that. Whether or not that worked out well or not for him because of how everything went down I do not know but neither do you ; ). Best wishes.
Two 50O k trades in last 30 mins
Has anyone seen the above context & WITHOUT the volatility typical for NWBO?
WHO is doing the
BUY?
SELL?
& WHY?
From a LEFTY to
Thanks Red_Right_Hand
DIFFERENT STROKES for DIFFERENT FOLKS
Do you have historical examples of such splits in M&A, and how did those work out?
Seems to me that a PR was sent to the "publisher" at 3:40 for a Monday morning release.
I've seen it before that these "publishers" have staff that trade on the "insider" info.
The only realistic scenario as I see it.
Doc- In my opinion a big pharma comes in with partnership for all cancers indications with upfront $ and 70/30 or whatever is appropriate. Once two or three trials become evident that this is real gem then by that time the PPS is high enough to justify 200% up to 400% mark up to buy the whole company.
-20K is reserved for legacy retail common to one future century wake up to their riches.
Well, soon they know NWBO would not wait for them Doc.
NWBO has more than one options. They should never forget that.
You snooze you lose.
FeMike That theory is absurd. You are saying they are going to buy from the local Lowes for construction on a on a huge scale and hundreds of freezers. The freezers are probably for the Labor Day weekend sales and college kids for their dormitories and the construction inventory is constantly being replenished especially when their buyers know that a priced increase may be coming. Stop the friggin BS. and get back to TEA leaf reading by the full moon with the local gypsy.
You're playing with words.
flipper44,
What if insider and friendly support made it impossible to buy at what favorable terms normally would look like? What if NWBO was looking for an upfront cash infusion plus 60 NWBO/40 MRK or 50/50 agreement on all future developed revenues or similar vs cash buyout?; ).
Off Topic:
$NVDA earnings next week ought to be fun!
It's the first time that CMF(15) has been positive in over 6 months.
There was a Gap during the day at the end. But no Gaps on the daily. Those are the Gaps that tend to get filled....the daily Gaps.
JMHO...
Thanks, thought I saw a small gap between 3:45 and 3:50 (just below .36 cents) It would be great if you are right and there was no gap.
The Direct patents are strong and relatively new.
The combination patent is strong and relatively new.
The flaskworks patents are new and very strong, and create a higher barrier to entry.
The new company we acquired seems like its IP will form a wider barrier to entry.
Our patents pending, particularly for hyperactive dendritic cells is very new.
The various exclusive use protections can go into effect upon any forthcoming approval.
The potential cancer indications are limitless.
Followers
|
1622
|
Posters
|
|
Posts (Today)
|
276
|
Posts (Total)
|
715421
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |